Sharing the Latest in Breast Cancer Care With Drs Rena Callahan and Jame Abraham

Jame Abraham, MD, of Cleveland Clinic, and Rena D. Callahan, MD, of UCLA, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Videos

Jame Abraham, MD, director of the Breast Oncology Program at Taussig Cancer Institute, co-director of the Cleveland Clinic Comprehensive Breast Cancer Program, and professor of medicine, Cleveland Clinic Lerner College of Medicine, discusses improving access to cancer therapy with biosimilars.

Access to cancer treatment is critical; however, the cost of cancer therapy stands as a significant barrier to many patients, says Abraham. Any means that could potentially lower these costs should be explored. Biosimilars have the potential to lower the cost of biologic agents which are largely unavailable to patients in developing countries.

A majority of cancer diagnoses are made in low- and middle-income countries, adds Abraham. Yet, these are the areas in which access to medication is the most difficult. Biosimilars are equally effective and potentially less expensive alternatives to biologic products. Current examples for biosimilars include those for granulocyte-colony stimulating factor and trastuzumab (Herceptin). These agents have the potential to impact the health system on a global scale, especially as provider confidence grows. However, their impact would be most evident in developing countries.

Dr. Abraham on Improving Access to Therapy With Biosimilars

Jame Abraham, MD, director of the Breast Oncology Program at Taussig Cancer Institute, and co-director of the Cleveland Clinic Comprehensive Breast Cancer Program, discusses a head cooling system that can be used to limit hair loss attributed to chemotherapy treatment for patients with breast cancer.

When it comes to chemotherapy, 80% of patients are concerned about losing hair, explains Abraham. The prospective cooling scalp study focuses on the Paxman Scalp Cooling System, which is a helmet device connected to a cooling machine.

In this randomized study, patients are connected to the cooling cap 30 minutes before chemotherapy, 30 minutes during, and then 90 minutes after treatment. This resulted in a 50% reduction in hair loss compared to the control arm, which resulted in 100% hair loss.

Jame Abraham, MD

Articles

Sharing the Latest in Breast Cancer Care With Drs Rena Callahan and Jame Abraham

Dr. Abraham on Improving Access to Therapy With Biosimilars

Dr. Abraham on Prevention of Hair Loss for Breast Cancer Chemotherapy